Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been diagnosed with a specific type of prostate cancer called adenocarcinoma that is contained within the prostate (localized)
- People whose prostate cancer diagnosis has been confirmed through a biopsy
- People whose cancer is classified as low to intermediate risk based on standard cancer guidelines, with a PSA blood test result below 20 ng/ml and a cancer grade of group 3 or lower
- People whose prostate is smaller than 60cc in size, as measured by an MRI scan taken during treatment planning
- People who are able to have an MRI scan and have a clearly identified area of concern in the prostate rated at a certain level on a standard imaging scale (PI-RADS score of 3 or higher) — though exceptions may apply for very low, low, or certain intermediate-risk cases (confirm with trial site)
- People who are able to understand and agree to participate by signing an informed consent form
- People who agree to use effective contraception methods (such as condoms and spermicidal foam, an intrauterine device, or their partner using prescription birth control pills)
- People whose treating radiation specialist determines that the rectal area can be properly prepared for treatment
Who may not be able to join:
- People whose prostate cancer is classified as high risk
- People whose cancer has spread to the lymph nodes in the pelvis
- People who require radiation treatment to the pelvic lymph nodes, as determined by their treating radiation specialist
- People who show signs that the cancer has grown outside the prostate or into nearby structures called seminal vesicles
- People who have previously had radiation treatment to the pelvis
- People who have had another cancer diagnosis within the last 5 years
- People whose prostate is larger than 60cc as measured on their planning MRI
- People with active significant inflammatory bowel disease or active rheumatological (joint/immune) disease
- People who have had previous prostate surgery, including a procedure called UroLift, or a procedure called TURP (a type of prostate surgery) within 6 months before the study treatment
- People who do not meet specific technical radiation dose limits during treatment planning
- People whose urinary, bowel, or erectile function scores fall below a certain level on a standard questionnaire given before treatment
- People of reproductive potential who do not agree to use effective contraception during the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jonathan Lischalk, NYU Langone Health
Phone: 212-496-5845
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Grade 2 or Higher Toxicities per CTCAE version 5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.